Want to see AU:TRJ full AI Analyst Report?
TRJ Stock Chart & Stats
AU$0.39
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.39
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.97
Previous CloseN/A
Volume3.68K
Average Volume (3M)21.61K
Market Cap
AU$32.10M
Enterprise ValueAU$152.36
Total Cash (Recent Filing)AU$12.78M
Total Debt (Recent Filing)AU$69.37M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding152,863,630
10 Day Avg. Volume15,523
30 Day Avg. Volume21,606
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.03
Price to Sales (P/S)0.65
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.83Price Target Upside111.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$181.07M
Bulls Say, Bears Say
Bulls Say
Consumables-driven Recurring RevenueA consumables-led model generates repeat orders from laboratories and industrial customers, producing more predictable, durable revenue streams. Over months this reduces reliance on one-off instrument sales, supports recurring cash flow, and helps stabilize demand through routine testing cycles across industries.
Modest But Consistent Revenue GrowthSustained mid-single-digit revenue growth reflects continued product uptake and market penetration in analytical consumables. Over a 2–6 month horizon this trend supports incremental scale, better absorption of fixed costs, and provides runway for targeted investments to improve operational efficiency.
Stable Balance Sheet With Moderate LeverageModerate debt and a stable equity base provide financial flexibility to fund working capital and modest capital expenditures without acute refinancing risk. This foundation helps the business weather cyclical lab spending and supports measured investments in product support and distribution over months.
Bears Say
Negative Net Income And ROEOngoing net losses and negative ROE erode retained earnings and limit internal funding capacity. Persisting unprofitability over several quarters constrains strategic flexibility, forces prioritization of cash conservation, and increases reliance on external capital to support operations and growth initiatives.
Declining Free Cash FlowA 20% fall in free cash flow signals weaker cash generation after operating and investing needs. Over a multi-month horizon this reduces capacity to reinvest, pay down debt, or cushion operational setbacks, potentially forcing tighter cost controls or external funding at unfavorable terms.
Weak Operating Margins (EBIT/EBITDA)Low EBIT/EBITDA margins indicate limited operating leverage and persistent cost pressures in production or service delivery. Even with revenue growth, margin compression constrains profitability convertibility and leaves the business vulnerable to input-cost inflation or pricing pressure from customers.
Trajan Group Holdings Ltd News
TRJ FAQ
What was Trajan Group Holdings Ltd’s price range in the past 12 months?
Trajan Group Holdings Ltd lowest share price was AU$0.19 and its highest was AU$0.97 in the past 12 months.
What is Trajan Group Holdings Ltd’s market cap?
Trajan Group Holdings Ltd’s market cap is AU$32.10M.
When is Trajan Group Holdings Ltd’s upcoming earnings report date?
Trajan Group Holdings Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 41 days.
How were Trajan Group Holdings Ltd’s earnings last quarter?
Trajan Group Holdings Ltd released its earnings results on Feb 25, 2026. The company reported AU$0.005 earnings per share for the quarter, beating the consensus estimate of -AU$0.004 by AU$0.009.
Is Trajan Group Holdings Ltd overvalued?
According to Wall Street analysts Trajan Group Holdings Ltd’s price is currently Undervalued.
Does Trajan Group Holdings Ltd pay dividends?
Trajan Group Holdings Ltd does not currently pay dividends.
What is Trajan Group Holdings Ltd’s EPS estimate?
Trajan Group Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trajan Group Holdings Ltd have?
Trajan Group Holdings Ltd has 152,863,630 shares outstanding.
What happened to Trajan Group Holdings Ltd’s price movement after its last earnings report?
Trajan Group Holdings Ltd reported an EPS of AU$0.005 in its last earnings report, beating expectations of -AU$0.004. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of Trajan Group Holdings Ltd?
Currently, no hedge funds are holding shares in AU:TRJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trajan Group Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Trajan Group Holdings Ltd
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.
TRJ Stock 12 Month Forecast
Average Price Target
AU$0.83
▲(111.54% Upside)
Technical Analysis
Compumedics Limited
―
Nanosonics Limited
―
Proteomics International Laboratories Ltd.
―
Genetic Signatures Ltd.
―
IDT Australia Limited
―